Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction)
Tóm tắt
The prognosis of locally advanced non-small cell lung cancer (NSCLC) treated with conventional radiotherapy remains poor. Hypofractionation reduces overall treatment time increasing biological effect in patients not suitable for concurrent chemo-radiotherapy. From January 2009 to October 2016, 76 inoperable locally advanced primary or recurrent NSCLC patients were treated with 60 Gy in 20 fractions of 3 Gy/each for 4 weeks as exclusive or post-chemotherapy treatment. Fifty-eight patients (76.3%) had stage III and 18 (23.7%) stage IV (≤ 2 metastases) disease: 63 primary (82.9%) and 13 recurrent (17.1%). Median and 2-year overall survival were 17 months and 38.9%, respectively. Median and 2-year loco-regional progression free survival were 27 months and 55.3%, respectively. Univariate and multivariate analyses demonstrated that patients with complete response presented better outcomes, whereas no statistically relevant difference was evidenced in terms of previous chemotherapy, recurrent vs primary disease, volume and stage. Thirty patients (39.5%) presented acute esophagitis (1—grade 3) and 19 (25.0%) acute pneumonitis (2—grade 3). Six patients (7.9%) developed grade 2–3 late pneumonitis and 3 patients (3.9%) grade 1 late esophagitis. In patients not suitable of concurrent radio-chemotherapy, exclusive or sequential hypofractionated schedule using 60 Gy in 20 fractions was well tolerated and presented promising results. Complete local response was a predictor of better outcomes, and any efforts will be made to perform prospective clinical trials to further evaluate hypofractionated regimens with increased lesional BED.
Tài liệu tham khảo
National Cancer Institute (2012–2016) SEER cancer statistics factsheets: lung and bronchus cancer. National Cancer Institute, Bethesda. http://seer.cancer.gov/statfacts/html/lungb.html
Le Pechoux C (2011) Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 16:672–681
Schwarzenberger P, Fariss A, Linares L, Nedzi L, Salazar OM (2011) Dose escalation of once weekly vinorelbine concurrent with weekly split dose hypofractionated chest radiation for palliation of advanced non-small cell lung cancer: a phase I/II study. Am J Med Sci 341:454–459
Jassem J (2007) The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol 83:203–213
Pemberton LS, Din OS, Fisher PM, Hatton MQ (2009) Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-center retrospective study of outcome. Clin Oncol 21:161–167
Matsuura K, Kimura T, Kashiwado K, Fujita K, Akagi Y, Yuki S, Murakami Y, Wadasaki K, Monzen Y, Ito A, Kagemoto M, Mori M, Ito K, Nagata Y (2009) Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer. Int J Clin Oncol 14:408–415
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199
Fowler JF, Chappell R (2000) Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 46:516–517
Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J (2001) A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 49:23–33
Valeriani M, Marinelli L, Reverberi C, De Sanctis V, Mollo D, Nicosia L, Osti MF (2019) Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule. Radiol Med 124(1):58–64
Zhu ZF, Fan M, Wu KL, Zhao KL, Yang HJ, Chrn GY, Jiang GL, Wang LJ, Zhao S, Fu XL (2011) A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol 98:304–308
Osti MF, Agolli L, Valeriani M, Falco T, Bracci S, De Sanctis V, Maurizi Enrici R (2013) Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiation Oncol Biol Phys 85(3):e157–e163
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyter S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Kaster TS, Yaremko B, Palma DA, Rodrigues GB (2015) Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 16(2):71–79
Graham MV, Pajak TE, Herskovic AM, Emami B, Perez CA (1995) Phase I/II study of treatment of locally advanced (T3/T4) noneoat cell lung cancer with concomitant boost radiotherapy by the radiation therapy oncology group (RTOG 83-12): long-term results. Int J Radiat Oncol Biol Phys 31:819–825
Nguyen LN, Komaki R, Allen P, Schea RA, Milas L (1999) Effectiveness of accelerated radiotherapy for patients with inoperable nonesmall cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review. Int J Radiat Oncol Biol Phys 44:1053–1056
Holloway CL, Robinson D, Murray B, Amanie J, Butts C, Smylie M, Chu K, McEwan AJ, Halperin R, Roa WH (2004) Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with nonesmall cell lung cancer. Radiother Oncol 73:285–287
McPartlin AJ, Chaudhry S, Swindell R, Bayman P, Burt P, Chittalia A, Cootes J, Faivre Finn C, Harris M, Lander H, Lee L, Sheikh H, Pemberton L (2013) The largest UK single centre series using hypofractionated radical radiotherapy for NSCLC in the very elderly. Lung Cancer 81:144
Din OS, Harden SV, Hudson E, Mohammed N, Pemberton SL, Lester JF, Biswas D, Magee L, Tufail A, Carruthers R, Sheikh GD, Hatton MQF (2013) Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiother Oncol 109:8–12
Jaksic N, Chajon E, Bellec J, Corre R, Ricordel C, de Latour B, Lena H, Schick U, de Crevoisier R, Castelli J (2018) Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer. Radiat Oncol 13(1):147
Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR (2015) Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer 16:156–163
Fondevilla Soler A, López-Guerra JL, Dzugashvili M, Sempere Rincón P, Sautbaet A, Castañeda P, Díaz JM, Praena-Fernandez JM, del Campo ER, Azinovic I (2017) Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced nonsmall cell lung cancer patients. Clin Transl Oncol 19(12):1469–1477. https://doi.org/10.1007/s12094-017-1689-z
Ji K, Zhao LJ, Liu WS, Liu ZY, Yuan ZY, Pang QS, Wang J, Wang P (2014) Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. Br J Radiol 87:20130562
Xu Y, Zheng X, Bai X, Li P, Ma H, Wang J, Hu X, Chen M (2017) Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: a retrospective study. Oncotarget 8(30):49084–49092
Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C (2007) Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43(1):114–121
Maguire J, Khan I, McMenemin R, Rourke ON, McNee S, Kelly V, Peedel C, Snee M (2014) SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radicalhypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer 50:2939–2949
Cho KH, Ahn SJ, Pyo HR, Kim K-S, Kum Y-C, Moon SH, Han JY, Kim HT, Koom WS, Lee JS (2009) A phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable non-small-cell lung cancer: results of Korean radiation oncology group 0301 study. Int J Radiat Oncol Biol Phys 74:1397–1404
Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM (2013) Dose-limiting toxicity after hypofractionated dose escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 31(34):4343–4348
Machtay M, Swann S, Komaki R, Albain K, Sause WT, Curran WJ (2005) Higher BED is associated with improved local-regional control and survival for NSCLC treated with chemoradiotherapy: an RTOG analysis. Int J Radiat Oncol Biol Phys 63(Suppl):S40